Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Leuk Lymphoma. 2020 Apr 8;61(7):1669–1677. doi: 10.1080/10428194.2020.1742900

Table 3.

Patient outcomes.

Variable
Median (range) or N (%)
Reason for discontinuation (n=12)
 Disease progression 9 (75%)
 Non-compliance 1 (8.3%)
 Toxicity 2 (17%)
Best response (n=11)
 Stable disease (SD) 9 (82%)
  SD ≥90 days 5 (45%)
 Progressive disease 2 (18%)
Duration of stable disease (n=9) 119 (56–429)